April 1, 2010
I BC’s sixth annual Cell Line Development and Engineering conference will deliver 37 presentations in a three-day, single-track format for the most valuable and intensive learning experience you can attend. This program has earned its reputation by attracting thought leaders in industry and academia to collectively examine and provide solutions to the industry’s most daunting challenges. For 2010, we developed an agenda that will help you achieve your ultimate goal of improving quality and understanding of your cell lines while reducing time and cost of development.
By joining us, you will hear exclusive case studies and data-driven presentations from Abbott, Amgen, Bayer, Biogen Idec, Centocor, Genzyme, Genentech, GSK, Lonza, MedImmune, Millennium, Pfizer, Regeneron, and more to help your company do the following:
Improve cell line stability and clone expression through vector redesign
Increase development speed with faster, more predictive screening
Integrate genomic techniques and technologies
Overcome timeline bottlenecks in development while improving quality and uniformity
Incorporate manufacturability to deal with difficult-to-express proteins
Apply design-of-experiment approaches to clone screening, media design, and development
Evaluate new mammalian and nonmammalian expression systems to look for viable alternatives to Chinese hamster ovary (CHO) cell lines
Generate cell lines that can stably and scalably express novel molecules
New this Year
IBC’s sixth annual Cell Line Development and Engineering event will focus on the next steps that await upstream scientists, engineers, and technical specialists. Several presenters will offer perspectives on different approaches and techniques companies are using to overcome the challenges of improving speed and quality. We will also explore the expression of novel molecules and discuss barriers to using new expression systems in hopes of determining whether viable options to CHO cells exist. In addition, we will examine the utility of statistical tools in cell line development.
Keynote Presentations
“Are There Drivers Left for Further Process Optimization in Cell Line Development?” by Michael W. Glacken (senior director of biologics process development at Millennium Pharmaceuticals): Now that production titers >5 g/L are being routinely reported, this address will examine other manufacturing attributes that could drive additional cell culture process development. Such drivers that will be examined include: manufacturing cost, development cycle times, raw material quality assurance, standardization, growth rate, design space, impurities, and regulatory relief.
“Beyond Just High Titers — The Future of Cell Line Engineering” by Matthew S. Croughan (George B. and Joy Rathmann professor and director of the Amgen Bioprocessing Center at Keck Institute): The breadth of cell line engineering is expanding to more directly address the goals of reduced variability in titers among different products, reduced levels of contaminating host cell proteins, simpler downstream processing, superior glycoforms, and faster and cheaper overall process and product development. These goals will be achieved through collaboration with others such as experts in bioreactor and medium design.
SCIENTIFIC ADVISORY BOARD
Gisela Chiang (principal scientist in clinical cellular engineering at Biogen Idec)
John H. Chon (senior director of BioProcess R&D at Percivia, LLC)
Kurt A. Droms (associate research fellow in global biologics at Pfizer Inc.)
Pamela Hawley-Nelson (associate director of process cell culture at Medlmmune)
John Joly (director of early stage cell culture in process development at Genentech, Inc.)
Kevin Kayser (R&D director in cell sciences and development at SAFC)
Kevin M. McCarthy (principal research scientist in drug substance development for Pfizer Biotherapeutics)
Pranhitha Reddy (scientific director of process and analytical sciences at Amgen Inc.)
Andrew Snowden (senior scientist in cell culture development at Biogen Idec)
You May Also Like
